Edap Tms SA · NASDAQ:FOCL
Edap Tms SA — H.C. Wainwright 28th Annual Global Investment Conference (August 2026)
21 slides from Edap Tms SA's conference presentation, August 2026
Slide 1: The Global Leader in Therapeutic Ultrasound
The Global Leader in Therapeutic Ultrasound 1
Slide 2: Forward-Looking Statements & Disclaimer
F OR W ARD -L OOKI NG Statements & Disclaimer This presentation has been prepared by EDAP TMS S.A., operating under the corporate name FocalTherics (Nasdaq: FOCL) (the “Company”), and is furnished for informational purposes only. Unless the context requires otherwise, references to “FocalTherics,” t
Slide 3: Global Leader in Therapeutic Ultrasound for the Treatment of Cancer and Benign Disease
Global Leader in Therapeutic Ultrasound for the Treatment of Cancer and Benign Disease Redefining the Treatment of Cancer and Benign Disease through Organ Sparing, Function Preserving Focal Therapy 3
Slide 4: Commitment to Focal Therapy
FOC US ING ON AC CELERA TI NG OUR GR OWT H EN GIN E Commitment to Focal Therapy HIFU Revenue ($) 40% Y/Y 60000 Growth 50000 HIFU +32% 3 yr $52M 40000 CAGR 30000 $37M 20000 $26M $22M 10000 $16M 0 CY22 CY23 CY24 CY25 CY26E Note: CY26E = Midpoint of CY26 Guidance Range Rei terated on August 13, 2026 4
Slide 5: Scalable Focal One Platform Enables Simultaneous Innovation
Scalable Focal One Platform Enables Simultaneous Innovation HIFU & Advanced Histotripsy Imaging Remote Robotics Connectivity AI-Driven Treatment 5
Slide 6: Prostate Cancer is the Most Common Cancer Among Men
Prostate Cancer is the Most Common Cancer Among Men1 >1.4 Million 2 New Cases Diagnosed Annually, Globally >330,000 New Cases Diagnosed Annually in the U.S. Annual Global Prostate 2.9M Diagnoses Will >3.5 Million Cases Men Living with Prostate Cancer in the U.S. DOUBLE 3 1.4M Cases by 2040 2020 2040
Slide 7: The Large Gap Between No Treatment and Radical Treatment
The Large Gap Between No Treatment and Radical Treatment Low Risk Intermediate Risk High Risk ~30% of patients1 ~50% of patients ~20% of patients No Treatment Radiation or Organ Removal Active Surveillance Radical or Salvage Treatment Previously, There Have Been No Options, Other Than Active Surveil
Slide 8: Prostate Cancer Patient Value Equation
FOC AL O NE® RO BOTIC HIFU Prostate Cancer Patient Value Equation Surgery HIGH Focal One Robotic HIFU Radiation Radical Treatments PROVEN EFFICACY (Cancer Control) Active Surveillance LOW HIGH QUALITY OF LIFE PRESERVATION (Urinary and Sexual Function Outcomes) 8
Slide 9: Treatment Comparison
Treatment Comparison Focal One HIFU Provides the Optimal Organ-Preserving Patient Treatment ORGAN-PRESERVING STRATEGY WHOLE-GLAND RADICAL TREATMENT STRATEGY Active Focal One® Surgery Surveillance Robotic HIFU Radiation Radical Prostatectomy CANCER 10-year Cancer Specific Survival N/A 95%(1) 91%(1) 9
Slide 10: Focal Therapy | The New Emerging Market
DRIVING A PA RADIGM SHIF T IN PROSTATE C ANC ER Focal Therapy | The New Emerging Market Future Market(2) Emerging Market(2) Focal Therapy Expected to Grow to Traditional Market(1) Focal Therapy (HIFU) Active ~40% Active Surveillance Surveillance of the Market Focal Active Therapy Surveillance Radica
Slide 11: HIFU: Fastest Growing Focal Therapy Treatment
HIFU HIFU Fastest Growing Focal Therapy Treatment1 Cryo #1 Ablation Technology for Prostate Cancer IRE (all organs)2 TULSA2 2021 2022 2023 2024 2025 [1] Based on Medicare clai ms utilization data publi shed by CMS in connection with the Hospital Outpatient Prospective Payment System (HOPPS) Proposed
Slide 12: Hospital Outpatient Medicare Payment
Hospital Outpatient Medicare Payment Procedure CPT® Code 2027 Payment (Proposed) Prostate Brachytherapy 55875 $6,292 Cryo Ablation 55873 $10,797 HIFU 55880 $10,797 +11.6% Laparoscopic/Robotic Prostatectomy 55866 $12,300 Medicare Payment (National Average). From CMS Hospital Outpati ent Prospective P
Slide 13: Favorable Physician Payment
Favorable Physician Payment Procedure CPT® Code Work RVU Physician Payment (2026) (Medicare - 2026) MRI Transurethral Ultrasound Ablation 55882 11.21 $530 Prostate Brachytherapy 55875 13.12 $693 Cryo 55873 13.26 $692 Irreversible Electroporation 55877 13.50 $675 HIFU 55880 17.29 $884 Laparoscopic/Ro
Slide 14: Focal One Adoption Accelerating at Major U.S. Hospitals
96 Focal One Systems as of Jun. 30, 2026 F OC AL O NE A DO P TIO N AC CEL ER ATI NG (44 Academic – 52 Community) At Major U.S. Hospitals 14
Slide 15: Focal One Adoption Accelerating at Major U.S. Hospitals
96 Focal One Systems as of Jun. 30, 2026 F OC AL O NE A DO P TIO N AC CEL ER ATI NG (44 Academic 300+ Hospitals –in52 Sales Community) Pipeline At Major U.S. Hospitals 15
Slide 16: Focal One Adoption at Major International Hospitals
88 Focal One Systems as of Jun. 30, 2026 F OC AL O NE A DO P TIO N AC CEL ER ATI NG 254 Focal One Treatment Clinical Sites At Major International Hospitals FOCAL ONE FIXED SITES FOCAL ONE MOBILE SITES 16
Slide 17: Expanded Indications of Focal One
S IN GLE PLAT FOR M, MULT IPL E IN DI CAT ION S Expanded Indications of Focal One Benign Prostatic Deep Infiltrating Hyperplasia (BPH) Endometriosis 38M 100+ Million1 Women Living with Deep Men Living with BPH Globally Infiltrating Endometriosis Globally2,3,4,5 13+ Million1 New Cases Diagnosed Annua
Slide 18: 4.3M+ Procedures and $10B+ Revenue TAM
Focal One Platform Expansion Opportunity Represents a TAM of 4.3M+1 Procedures and $10B+ Revenue 480K (O.U.S) Endometriosis 235K (U.S.) BPH 1.5M (O.U.S) 400K (U.S.) > 4.3M Procedures 1.7 M (Global) Prostate Cancer [1] Management Estimates; data on fi le. 18
Slide 19: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights $13.2M 44% 184 HIFU Revenue Y/Y Growth Global Installed Base 39% Y/Y Growth 13 Focal One System Sales 47% 55.6% Y/Y Procedure Gross Margin Volume Growth +444 bps Y/Y ESWL & DISTRI BUTION NOW C LASSIFIED UN DER D IS CON T INUED OPERAT IO NS 19 19
Slide 20: 2028E Target Model Financial Framework
2028E Target Model Financial Framework Focused on Driving Positive EBITDA and Breakeven Operating Income to Deliver Shareholder Value CY25 Actual CY28E Target Range Revenue $37M ~ 40%+ 3-Yr CAGR (+/- 3%) Gross Margin 48.1% ~60% (+/- 200 bps) Operating Income ($21M) Breakeven EBITDA ($19M) Positive I
Slide 21: The Global Leader in Therapeutic Ultrasound
The Global Leader in Therapeutic Ultrasound 21